Is switching biologics in CRSwNP promising?: Real-world evidence for clinical outcome measures in comparison
Objective: Biologics are well established in treating severe chronic rhinosinusitis with nasal polyps (CRSwNP). Most patients benefit from the first chosen biologic agent, in a few cases switching biologics can be a further therapeutic strategy. - Methods: In this monocentric retrospective study, pa...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
2026
|
| In: |
ENT
Year: 2026, Pages: 1-8 |
| ISSN: | 1942-7522 |
| DOI: | 10.1177/01455613261438970 |
| Accesso online: | Verlag, kostenfrei, Volltext: https://doi.org/10.1177/01455613261438970
|
| Note sull'autore: | Kornmann Jonas, MD, Kramer Benedikt, MD, Rotter Nicole, MD, Seiz Elena, MD, Scherl Claudia, MD, and Zaubitzer Lena, MD |
| Riassunto: | Objective: Biologics are well established in treating severe chronic rhinosinusitis with nasal polyps (CRSwNP). Most patients benefit from the first chosen biologic agent, in a few cases switching biologics can be a further therapeutic strategy. - Methods: In this monocentric retrospective study, patients with CRSwNP and biologic therapy were compared with respect to Sino-Nasal Outcome Test-22 (SNOT-22) score, bilateral nasal polyp score (NPS), and change in biologic agent as primary variables. Statistical analysis was performed using independent sample t-tests or Welch’s t-tests for continuous variables and Pearson’s chi-squared test for categorical data. - Results: A total of 48 patients with CRSwNP who received biologic therapy between 2020 and 2024 were included in this study. During the course of treatment, 10 patients (20.4%) required a switch to a different biologic agent. A significant reduction in both the SNOT-22 score and NPS was observed in patients regardless of whether a biologic switch occurred, following a minimum post-treatment observation period of 6 months. No significant differences in clinical outcomes were found between patients who switched biologics and those who continued with their initial agent. - Conclusions: Most patients switched from anti-immunoglobulin E or anti-IL-5 treatment to anti-IL-4/-IL-13, with good improvement in therapy control. Notably, symptom control after switching biologics does not differ significantly from that achieved in patients who remained on their initial biologic therapy. |
|---|---|
| Descrizione del documento: | Erstmals veröffentlicht: 16. Mai 2026 Gesehen am 16.06.2026 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1942-7522 |
| DOI: | 10.1177/01455613261438970 |